[HTML][HTML] Multifunctional opioid-derived hybrids in neuropathic pain: Preclinical evidence, ideas and challenges
J Starnowska-Sokół, B Przewłocka - Molecules, 2020 - mdpi.com
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges.
J Starnowska-Sokół, B Przewłocka - Molecules (Basel, Switzerland), 2020 - europepmc.org
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
[PDF][PDF] Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges
J Starnowska-Sokół, B Przewłocka - Molecules, 2020 - pdfs.semanticscholar.org
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges
J Starnowska-Sokół… - Molecules (Basel …, 2020 - pubmed.ncbi.nlm.nih.gov
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia-which is estimated to relate to more than half of the patients …
induce efficient analgesia-which is estimated to relate to more than half of the patients …
Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges.
J Starnowska-Sokół, B Przewłocka, T Plech… - …, 2020 - search.ebscohost.com
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
[PDF][PDF] Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges
J Starnowska-Sokół, B Przewłocka - Molecules, 2020 - scholar.archive.org
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
Multifunctional opioid-derived hybrids in neuropathic pain: preclinical evidence, ideas and challenges
J Starnowska-Sokół, B Przewłocka - Molecules, 2020 - ruj.uj.edu.pl
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …
[HTML][HTML] Multifunctional Opioid-Derived Hybrids in Neuropathic Pain: Preclinical Evidence, Ideas and Challenges
J Starnowska-Sokół, B Przewłocka - Molecules, 2020 - ncbi.nlm.nih.gov
When the first-and second-line therapeutics used to treat neuropathic pain (NP) fail to
induce efficient analgesia—which is estimated to relate to more than half of the patients …
induce efficient analgesia—which is estimated to relate to more than half of the patients …